streptococcus

Isobavachromene is an inhibitor of NADH-Ubiquinone oxidoreductase and ornithine decarboxylase. Isobavachromene has antifungal activity.

Sapienic acid sodium is a fatty acid with variable antimicrobial activities against Gram-positive and Gram-negative bacteria found on the skin and in the oral cavity.

Cefuroxime Sodium is the sodium salt form of cefuroxime and a semi-synthetic, broad-spectrum, beta-lactamase resistant, second-generation cephalosporin antibiotic with bactericidal activity. Cefuroxime sodium (Cefuroxime sodium salt) inhibits bacterial cell wall synthesis by inactivating penicillin binding proteins (PBPs) thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of the cell wall. Lack of cross-linking results in a reduction of cell wall stability and leads to cell lysis.

Sapienic acid, a fatty acid commonly found on the skin and in the mucosa, is active against Streptococcus sanguinis, Streptococcus mitis, and Fusobacterium nucleatum, with MBC values of 31.3 μg/mL, 375.0 μg/mL, and 93.8 μg/mL, respectively.

Oritavancin diphosphate (LY333328 diphosphate) is a novel semisynthetic glycopeptide antibiotic developed for treating serious Gram-positive bacterial infections.

Tebipenem Pivoxil (Orapenem) , an orally activity carbapenem antibiotic, is utilized in treating otolaryngologic and respiratory infections.

Gentamicin sulfate (SCH9724) is a broad-spectrum, orally administered aminoglycoside antibiotic that exhibits inhibitory activity against aerobic Gram-negative bacteria by interfering with mRNA translation.

Solithromycin (OP-1068) is an orally bioavailable antimicrobial agent that inhibits cell viability, protein synthesis, and growth rate of Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus aureus, and Haemophilus influenzae with IC50 values of 7.5 ng/mL, 40 ng/mL, and 125 ng/mL, respectively.Solithromycin inhibits protein biosynthesis by binding to the large 50S subunit of the ribosome.

Cefuroxime (Cephuroxime) is an orally active second-generation cephalosporin antibiotic with antimicrobial activity that inhibits both Gram-positive and Gram-negative bacteria, and is used in the study of soft tissue infections.

Moxifloxacin (Avelox) is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae.

Linezolid (PNU-100766), the first of the oxazolidinone class, is a synthetic antibiotic used for the therapy of infections resulted from multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and streptococcus. The drug takes effect as the inhibitor of the initiation of bacterial protein synthesis.

D-Cysteine, the D-isomer of cysteine, is a powerful inhibitor of E. coli growth and is mediated by D-amino acid oxidase to produce H2S, serving as a neuroprotective agent against cerebellar ataxia. Additionally, D-cysteine can inhibit the growth and cariogenicity of a two-species biofilm formed by Streptococcus mutans and Streptococcus hemoglobin.

3,5-Dimethylbenzaldehyde has broad-spectrum antimicrobial activity, inhibiting Bacillus subtilis, Pseudomonas albicans, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pneumoniae.

Delafloxacin (WQ-3034) (RX-3341, ABT-492) is a fluoroquinolone antibiotic agent. It has potent inhibitory against levofloxacin-resistant Streptococcus pneumoniae strains (MIC: 0.0078-0.125 μg/ml).

Copper(Ⅱ) Sulfate (Cupric sulfate) has a variety of antibacterial activities and has inhibitory activity against Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, Plasmodium falciparum, etc.

Epiroprim (Ro11-8958) is a selective dihydrofolate reductase (DHFR) inhibitor with antibacterial activity, inhibiting Staphylococcus, Enterococcus, Pneumococcus, and Streptococcus.

G43 is a potent and selective glucosyltransferase inhibitor that inhibits GtfB and GtfC with Kd values of 3.7 μM and 46.9 nM, respectively.G43 exhibits in vitro and in vivo anti-Streptococcus mutans activity and can be used for caries studies.

Faropenem daloxate (Faropenem medoxil) is useful for penem and antibiotics. Faropenem medoxomil has excellent in vitro activity against Streptococcus pneumoniae, Haemophilus influenzae and other key pathogens implicated in acute bacterial rhinosinusitis.Faropenem daloxate is the first oral penem in a new class of beta-lactam antibiotics.

Zabofloxacin is a potent and seletive bacterial type II and IV topoisomerases inhibitor, and has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes and S.pneumonia.

Zabofloxacin hydrochloride is a potent and seletive bacterial type II and IV topoisomerases inhibitor, has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes and S.pneumonia.

AZD9567 is a potent and orally active and selective non-steroidal glucocorticoid receptor modulator (SGRM) with an IC50 value of 3.8 nM.It has demonstrated excellent efficacy in the Streptococcus cell wall (SCW) reactivation model of joint inflammation.

Gemifloxacin mesylate (Gemifloxacin mesylate) inhibits activities of DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and eventually bacterial growth. Gemifloxacin Mesylate is the mesylate salt form of gemifloxacin, a synthetic broad-spectrum fluoroquinolone with antibacterial activity. This fluoroquinolone exerts an enhanced spectrum of activity against gram-positive bacteria such as Streptococcus pneumonia and Staphylococcus aureus, in addition to its activity against gram-negative bacteria.

Cefditoren is an antibiotic characterized by its oral efficacy and broad-spectrum antimicrobial activities, effectively inhibiting both Gram-negative and Gram-positive bacterial activities. It displays a MIC50 of 0.25-0.5 mg/L against Streptococcus pneumoniae strains. Additionally, Cefditoren is utilized in treating respiratory and skin infections.

Nafithromycin (WCK 4873) serves as an orally administered antibiotic effective against community-acquired pneumonia organisms such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin-susceptible Staphylococcus aureus. It displays a minimum inhibitory concentration (MIC 90) of 0.12 mg/liter against both macrolide-resistant and telithromycin-insensitive Streptococcus pneumoniae.